Heartburn treatment in primary care: randomised, double blind study for 8 weeks.
OBJECTIVE
To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients.


METHODS
Randomised, double blind, placebo controlled study.


METHODS
65 primary care practices in Norway.


METHODS
483 untreated patients with complaints of heartburn >/=3 days a week, with at most grade 1 reflux oesophagitis.


METHODS
Omeprazole 20 mg once daily, cisapride 20 mg twice daily, or placebo for 8 weeks.


METHODS
Adequate control of heartburn, defined as </=1 day of the past 7 days with no more than mild heartburn, after 4 weeks of treatment.


RESULTS
In the all patients treated analysis, adequate control of heartburn was achieved in 71% of patients taking omeprazole, 22% taking cisapride, and 18% taking placebo after 4 weeks of treatment (omeprazole v cisapride and placebo, P<0.0001; cisapride v placebo, non-significant). Results were comparable in patients with or without reflux oesophagitis. In patients treated with omeprazole only, symptom control was achieved significantly more often in patients positive for Helicobacter pylori. Antacid use was 2-3 times greater in patients taking cisapride or placebo than in those taking omeprazole. Relief of non-reflux symptoms did not significantly differ between the three groups. Significantly more patients taking cisapride reported adverse events than those taking omeprazole or placebo.


CONCLUSIONS
Omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo.
Hatlebakk
J G
JG
Department of Medicine, Haukeland Sykehus, University of Bergen, N-5021 Bergen, Norway.
Hyggen
A
A
Madsen
P H
PH
Walle
P O
PO
Schulz
T
T
Mowinckel
P
P
Bernklev
T
T
Berstad
A
A
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D020117:Cisapride / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006356:Heartburn / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009664:Norway; D009853:Omeprazole / Q000627:therapeutic use*; D011320:Primary Health Care; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D009853:Omeprazole; D020117:Cisapride